MD-CERTIS-BIOLOGICALS
11.8.2021 15:19:08 CEST | Business Wire | Press release
To meet the rising demand for biological-based crop protection products, Certis Biologicals today announced new additions to its headquarters team. Tarang Srivastava begins immediately as Head of International Business, responsible for business strategy and financial objectives in international markets and working with distribution partners, external business partners and internal teams to expand biologicals globally. Srivastava’s focus will lay in providing solutions to growers in European markets. Srivastava formally worked on Bharat Certis Insecticide Limited for parent company Mitsui & Co. and brings extensive experience in establishing global positions to the new role.
Additionally, Certis Biologicals welcomes Moto Mitani to the International Business Team. Mitani will lead the Certis teams for Asia and Africa as well as supporting Certis Biologicals’ Specialty Chemical Sales division. Mitani joins from Mitsui AgriScience where he served as Business Manager responsible for international sales.
Amanda Eade joins the Global Marketing Team as Global Portfolio Manager for Bioinsecticides and Bioherbicides, assessing market capacity for Certis’ proven portfolio of bio-based insecticide and herbicide solutions, including Bt portfolio products, Firefighter© , Requiem Prime© and Homeplate© . Eade brings extensive experience from posts with Open Book Extracts as Operations Manager, BASF as portfolio manager and Dow Agrisciences as sales representative.
“Currently, Certis Biologicals distributes bio-based solutions in more than 50 countries worldwide and we see a growing need in areas where synthetic chemistries are growing scarce and regulations are high,” says Amy O’Shea, President and CEO. “We want to ensure that every grower, no matter where they are located, has access to our portfolio and we believe these additions to our staff will be key to achieving that goal.”
The additions of Srivastava, Mitani and Eade come in the wake of Certis Biologicals’ announcement that Rob Gibson joined as Global Product Manager and Ryutaro Matsuhashi, VP of International Business, had expanded his role within the biologicals leader to focus on growth in Latin America. In that capacity, Matsuhashi has seen success in expanding the company’s portfolio in Brazil.
“We are proud to be headquartered in the U.S., but Certis Biologicals is a true global distributor of biologicals,” says O’Shea. “We are investing in the talent and expertise needed to ensure that we can be the full-line provider of biologicals to all growers and distributors.”
Currently, Certis Biologicals innovates across six technology platforms, including bacteria-based technologies, fungi-based products, virus technologies, bacteriophage technologies, biochemicals and need-seed extracts. The company distributes nearly 40 integrated biological crop protection solutions to growers in more than 50 countries. Certis’ robust research and development pipeline is planning numerous new products and formulations coming to market over the next 3-5 years.
Growers and distributors who are interested in Certis Biologicals can visit www.CertisBio.com to learn more about the company’s portfolio of bio-solutions for organic and conventional farming.
About Certis Biologicals
Certis Biologicals is the leading manufacturer, innovator, developer and marketer of proven biological solutions for use in commercial agriculture and the garden and greenhouse markets.
With biological products sold through a global distribution network and in collaboration with various technology, regulatory and sourcing companies in more than 50 countries, Certis Biologicals meets the challenges faced by today’s growers around the globe to feed a growing population while sustaining the natural resources and environments necessary for a healthy planet.
To learn more about Certis Biologicals, their portfolio of proven solutions, or their commitment to sustainability, visit www.CertisBio.com or follow the company through social media on Facebook , Twitter , LinkedIn and Instagram .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210811005074/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health24.4.2026 18:52:00 CEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher24.4.2026 16:37:00 CEST | Press release
Compass is the most advanced company in classic psychedelics and has generated positive data from two ongoing large, well controlled Phase 3 clinical trials, designed to uphold the highest regulatory standardsFDA grants Compass NDA rolling submission and review request, based on Phase 3 dataCNPV awarded for COMP360, Compass’ proprietary formulation of synthetic psilocybin, for treatment-resistant depression (TRD)CNPV further accelerates momentum and Compass is confident and ready to deliver for patients Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD). Companies selected for the voucher program will be en
Banma Intelligence and Alipay Launch AI Cockpit Solution Powered by Alipay AI Pay, Enabling Seamless and Secure In-Car Transactions by Voice24.4.2026 16:04:00 CEST | Press release
At the 2026 Beijing International Automotive Exhibition (“Auto China 2026”), OS and AI technology company Banma Intelligence and Alipay today launched a new AI cockpit solution integrating Alipay AI Pay, enabling drivers to complete purchases by voice command directly from their vehicle. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424618328/en/ Industry-first AI Cockpit Solution with Alipay AI Pay Unveiled “In the past two years, smart cockpits have achieved rapid advances in perception and decision-making,” said Ming Cai, Banma Intelligence Chief Product Officer. “With large models onboard, vehicles can understand user intent and make recommendations. By integrating Alipay AI Pay into our AI cockpit solution, we are removing the last friction point in the in-car smart cockpit experience - drivers simply speak to pay, no phone required.” The new AI cockpit solution initially covers two high-frequency use cases: enterta
Spatial Announces the Release 2026 1.0.1: New Enhancements Across 3D InterOp, Data Prep, Meshing, and 3D Modeling SDKs24.4.2026 15:21:00 CEST | Press release
Spatial Corp., the leading software development kit provider for design, manufacturing and engineering solutions and a subsidiary of Dassault Systèmes, today announced new enhancements across several of its product lines. These updates further strengthen Spatial’s commitment to delivering high-performance solutions that optimize interoperability, data preparation, and advanced modeling workflows. Designed to improve efficiency and robustness across CAD translation, modeling, meshing, and simulation processes, the latest updates introduce expanded format support, enhanced PMI handling, and new capabilities for complex geometry processing. 3D InterOp NX Reader Enhancement for 2D Drawings The NX reader imports 2D drawings as visualization data from NX 2412 and later versions. glTF Writer Supports Draco Compression glTF export incorporates Draco compression for meshes and point-clouds to significantly reduce output file sizes. Enhanced Support for Reading Product Manufacturing Information
Meta Signs Agreement With AWS to Power Agentic AI on AWS Graviton Chips24.4.2026 14:10:00 CEST | Press release
The deal helps power the agentic workloads behind Meta’s AI effortsKey takeaways The deployment starts with tens of millions of Graviton cores, with the potential to expand. Meta is now one of the largest Graviton customers in the world. The deal builds on Meta's long-standing AWS relationship and use of Amazon Bedrock at scale to support its next generation of AI. Meta has signed an agreement to deploy AWS Graviton processors at scale. The deal marks a significant expansion of a long-standing partnership between the two companies as Meta builds its next generation of AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424641117/en/ The deployment starts with tens of millions of Graviton cores, with the flexibility to expand as Meta's AI capabilities grow. The deal reflects a shift in how AI infrastructure gets built: while GPUs remain essential for training large models, the rise of agentic AI is creating massive demand f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom